Insider Buying: Evolus (NASDAQ:EOLS) Director Buys $204,600.00 in Stock

Evolus, Inc. (NASDAQ:EOLS) Director Brady Stewart bought 30,000 shares of the company’s stock in a transaction on Friday, August 15th. The stock was bought at an average cost of $6.82 per share, for a total transaction of $204,600.00. Following the completion of the acquisition, the director directly owned 88,629 shares of the company’s stock, valued at approximately $604,449.78. This represents a 51.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Evolus Trading Up 1.4%

Evolus stock opened at $7.23 on Thursday. The company has a current ratio of 2.27, a quick ratio of 1.86 and a debt-to-equity ratio of 22.00. The business’s fifty day simple moving average is $8.72 and its two-hundred day simple moving average is $10.72. Evolus, Inc. has a 12 month low of $5.71 and a 12 month high of $17.82. The company has a market capitalization of $467.64 million, a price-to-earnings ratio of -7.38 and a beta of 1.12.

Wall Street Analyst Weigh In

EOLS has been the topic of several analyst reports. HC Wainwright dropped their target price on Evolus from $27.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Needham & Company LLC restated a “hold” rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, August 6th. Wall Street Zen cut Evolus from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Finally, BTIG Research decreased their price target on Evolus from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.25.

Institutional Trading of Evolus

A number of hedge funds have recently bought and sold shares of EOLS. Geode Capital Management LLC increased its position in Evolus by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company’s stock valued at $13,412,000 after acquiring an additional 3,969 shares during the last quarter. Wells Fargo & Company MN increased its position in Evolus by 41.6% during the fourth quarter. Wells Fargo & Company MN now owns 49,347 shares of the company’s stock valued at $545,000 after acquiring an additional 14,506 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Evolus during the fourth quarter valued at $575,000. Barclays PLC increased its position in Evolus by 12.9% during the fourth quarter. Barclays PLC now owns 105,786 shares of the company’s stock valued at $1,167,000 after acquiring an additional 12,124 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in Evolus by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock valued at $378,000 after acquiring an additional 2,044 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.